A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)

Hiroaki Yanagimoto,Hideyoshi Toyokawa,Daisuke Sakai,Hiroshi Wada,Sohei Satoi,Tomohisa Yamamoto,Hiroaki Nagano,Masanori Toyoda,Tetsuo Ajiki,Hironaga Satake,Akihito Tsuji,Atsushi Miyamoto,Masanori Tsujie,Shigekazu Takemura,Kazuhiro Yanagihara,Tatsuya Ioka

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)

2018

Hiroaki Yanagimoto
Hideyoshi Toyokawa
Daisuke Sakai
Hiroshi Wada
Sohei Satoi
Tomohisa Yamamoto
Hiroaki Nagano
Masanori Toyoda
Tetsuo Ajiki
Hironaga Satake
Akihito Tsuji
Atsushi Miyamoto
Masanori Tsujie
Shigekazu Takemura
Kazuhiro Yanagihara
Tatsuya Ioka

Purpose To determine the recommended dose (RD) of gemcitabine (GEM) plus S-1 (GS) in curatively resected biliary tract cancer (BTC) patients without major hepatectomy.

Keywords:

Cancer
Hepatectomy
Biliary tract
General surgery
Adjuvant
Pharmacology
Gemcitabine
Medicine
Chemotherapy
Resection
Survival rate
Gastroenterology
adjuvant chemotherapy
Regimen
Neutropenia
biliary tract cancer
Internal medicine
Discontinuation
Planned Dose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations